MTA3和E-cadherin在宫颈癌转移中的作用研究  

Study the Relationship between the Expression of MTA3 and E-caderin on the Metastasis of Cervical Cancer

作　　者：黄海花[1] 吴秀浅[2] 李振华[1] 郑志超[1] 张薇[1] 

机构地区：[1]汕头大学医学院第二附属医院,广东汕头515041 [2]汕头大学医学院附属肿瘤医院

出　　处：《中国医学创新》2016年第28期14-18,共5页Medical Innovation of China

基　　金：广东省医学科学技术研究基金(A2013409)

摘　　要：目的：研究MTA3及E-cadherin蛋白在宫颈癌中的表达,并分析两者间的相互关系。方法：利用免疫组化染色SABC法检测68例人体宫颈癌标本中MTA3和E-cadherin蛋白的表达。结果：MTA3蛋白的表达与宫颈癌的组织学分级有密切关系（字~2=4.484,P=0.034）,与患者的年龄、肿瘤的组织学分级、临床分期、是否有淋巴结或远处转移无关（P〉0.05）。肿瘤组E-cadherin存在表达减少或丢失的比率明显高于正常对照组（字~2=21.761,P=0.00003）,并与淋巴结转移有密切关系（字~2=14.686,P=0.0001）,而与患者的年龄、肿瘤的组织学分级、临床分期及远处转移等无关（P〉0.05）。在宫颈癌组织中,MTA3与E-cadherin的表达呈正相关（r=0.579,P=0.0002）。结论：E-cadherin蛋白表达减少或缺失与宫颈癌浸润转移具有良好的相关性,MTA3表达下调的宫颈癌细胞可能更具侵袭潜能,MTA3可能是宫颈癌EMT启动调控的因素之一。Objective： To explore the expression of MTA3 and E-cadherin, to analyse potential correlation between these two proteins in cervical cancer.Method： 68 patients with cervical cancer of MTA3 and E-cadherin expression were analyzed by immunohistoehemieally.Result： The expression of MTA3 was closely related to cervical cancer histological grading （ X2=4.484, P=0.034 ）, it was not related to the age, tumor histological grade, clinical stage, lymph node metastasis or distant metastasis （ P〉0.05 ） .In tumor group, the rate of loss or low expression of E-cadherin was significantly higher than that of normal control group （ X2=21.761, P=0.00003 ）, which had close relation with lymph node metastasis （ x2=14.686, P=0.0001 ）, it was not related to the age, tumor histological grade, clinical stage or distant metastasis （ P〉0.05 ） .In cervical cancer tissues, the expression of MTA3 had a positive correlation with the expression of E-cadherin （ r=0.578, P=0.0002 ） .Conclusion： There are good correlation between loss or low expression of E-cadherin expression and cervical cancer metastasis.Cervical cancer cells that have low expression of MTA3 may be more aggressive.MTA3 may be one of the factors of cervical cancer EMT launch control.

关 键 词：子宫颈癌 转移相关因子3 上皮间质化 转移 

分 类 号：R737.33[医药卫生—肿瘤]